Overall survival of patients with non-small cell lung cancer after surgery treatment

Olivera Lončarević; Slobodan Aćimović; Jelena Vuković; Marko Stojisavljević; Nebojša Marić; Slobodan Lončarević; Marina Petrović; Ivana Milivojević; Gordana Ignjić; Gordana Milić; Leonida Mirilo; Nemanja Rančić

doi:10.2298/VSP161226043L

Olivera Lončarević Military Medical Academy, Pulmonology Clinic, Belgrade, Serbia
Slobodan Aćimović Military Medical Academy, Pulmonology Clinic, Belgrade, Serbia
Jelena Vuković Military Medical Academy, Pulmonology Clinic, Belgrade, Serbia
Marko Stojisavljević Military Medical Academy, Pulmonology Clinic, Belgrade, Serbia
Nebojša Marić Military Medical Academy, Clinic for Chest Surgery, Belgrade, Serbia
Slobodan Lončarević Military Medical Academy, Clinic for Maxillofacial Surgery, Belgrade, Serbia
Marina Petrović Clinical Center „Kragujevac“, Center for Pulmonary Diseases, Kragujevac, Serbia
Ivana Milivojević Special Hospital for Lung Disease „Ozren“, Sokobanja, Serbia
Gordana Ignjić PHO Hospital „Sveti vračevi“, Department of Pulmonology, Bijeljina, Bosnia and Herzegovina
Gordana Milić Military Medical Academy, Pulmonology Clinic, Belgrade, Serbia
Leonida Mirilo BELhospice – Center for Palliative Care and Palliative Medicine, Belgrade, Serbia
Nemanja Rančić Military Medical Academy, Centre for Clinical Pharmacology, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP161226043L

Keywords: carcinoma, non-small-cell lung;, adenocarcinoma;, squamous cell carcinoma;, survival;, recurrence.

Abstract

Background/Aim. Lung cancer is one of the most common malignant tumors. About 80% of all lung cancers are non-small cell lung cancer (NSCLC). According to histopathological characteristics, the most common types of NSCLC are squamous cell carcinoma and adenocarcinoma. The aim of this study was to evaluate the overall survival rate in the NSCLC patients initially received surgery according to its histopathological type and T – primary tumor, N –regional lymph nodes, M – distant metastasis (TNM) stages which were treated with surgical treatment, and after that, according to the TNM stage, chemotherapy protocols and/or radiation therapy. Methods. This retrospective case series study included all patients with NSCLC admitted to the Military Medical Academy in Belgrade in the period 2010–2015. A total number of selected patients was 85 (27 females and 58 males). Results. Out of 41 patients with squamous cell carcinoma, 19.5% deceased. On the other hand, in the group of patients with adenocarcinoma, 43.2% out of 44 patients deceased. The average cumulative survival was statistically significantly lower in the adenocarcinoma patients in comparison to the patients with squamous cell carcinoma (1,605.2 vs.1,304.8 days; p = 0.005). On the other hand, the average cumulative survival was statistically significantly lower in our patients in the recurrence group with adenocarcinoma in comparison to the recurrence group with squamous cell carcinoma (1,212.8 vs. 1,835.5 days; p = 0.032). Conclusion. Adenocarcinoma is more aggressive cancer in comparing to squamous cell carcinoma with lower overall survival in comparing to squamous cell carcinoma. Additional studies are needed to identify risk factors for recurrence after surgery, and to additionally explain role of tumor markers and molecular biological techniques in the progression of this kind of cancer.

References

American Cancer Society. Cancer facts and figures. 2016. Availa-ble from: http://www.cancer.org/acs/groups/content/@research /do-cuments/document/acspc-047079.pdf

Fenchel K, Sellmann L, Dempke WC. Overall survival in non-small cell lung cancer-what is clinically meaningful? Transl Lung Cancer Res 2016; 5(1): 115–9.

Global Burden of Disease Cancer Collaboration. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, Regional, and National Cancer Incidence, Mortali-ty, Years of Life Lost, Years Lived With Disability, and Disa-bility-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 2017; 3(4): 524–8.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Can¬cer statistics, 2008. CA Cancer J Clin 2008; 58(2): 71–96.

Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage dis-tri¬bution for patients with non-small cell lung cancer: a Na-tional Cancer Database survey. J Thorac Oncol 2010; 5(1): 29–33.

Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organization classification of tumours. Pathol-ogy and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.

Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Wal-dron W. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesede, MD: National Cancer Insti-tute; 2009. Available from: http://seer.cancer.gov/csr/1975_2009_pops09/

Milašinović G. Nationality guidelines of good clinical practice: Lung cancer. Belgrade: National Expert Commission for the Development and Implementation of Good Clinical Practice Guide; 2012. (Serbian) Available from: http://www.zdravlje.gov.rs/downloads/2011/Decembar/

Vodici/Vodic%20za%20dijagnostikovanje%20i%20lecenje%

karcinoma%20pluca.pdf

Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83(5): 584–94.

Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Van¬steenkiste J, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung can-cer. N Engl J Med 2004; 350(4): 351–60.

Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): A systematic review. Thorax 2001; 56(8): 628–38.

Strand T, Brunsvig PF, Johannessen DC, Sundstrøm S, Wang M, Horn¬slien K, et al. Potentially curative radiotherapy for non-small-cell lung cancer in Norway: A population-based study of survival. Int J Radiat Oncol Biol Phys 2011; 80(1): 133–41.

Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, et al. Radiotherapy alone versus combined chemo-therapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Can¬cer Inst 1991; 83(6): 417–23.

Durm G, Hanna N. Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am 2017; 31(1): 71–81.

Heist RS. First-Line Systemic Therapy for Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am 2017; 31(1): 59–70.

Tam K, Daly M, Kelly K. Treatment of Locally Advanced Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am 2017; 31(1): 45–57.

Chuang JC, Liang Y, Wakelee HA. Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am 2017; 31(1): 31–44.

Park SJ, More S, Murtuza A, Woodward BD, Husain H. New Tar¬gets in Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am 2017; 31(1): 113–29.

Pisters KM, Le Chevalier T. Adjuvant chemotherapy in com-pletely resected non-small-cell lung cancer. J Clin Oncol 2005; 23(14): 3270–8.

Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111(6): 1710–7.

Crinò L, Weder W, van Meerbeeck J, Felip E. ESMO Guidelines Working Group. Early stage and locally advanced (non-me¬ta-static) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v103–15.

Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for ad-van¬ced non-small-cell lung cancer. N Engl J Med 2002; 346(2): 92–8.

Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61(4): 212–36.

Kawase A, Yoshida J, Ishii G, Nakao M, Aokage K, Hishida T, et al. Differences between squamous cell carcinoma and adeno-carcinoma of the lung: Are adenocarcinoma and squamous cell carcinoma prognostically equal. Jpn J Clin Oncol 2012; 42(3): 189–95.

American Cancer Society. Non-small cell lung cancer stages. [cit-ed 2016 May 16]. Available from: http://www.cancer.org/cancer/lungcancer-non-smal¬l-cell/detailedguide/non-small-cell-lung-cancer-survival-rates

Sasaki H, Suzuki A, Tatematsu T, Shitara M, Hikosaki Y, Okuda K, et al. Prognosis of recurrent non-small cell lung cancer fol-lowing complete resection. Med Lett 2014; 7(4): 1300–4.

Uramoto H, Tanaka F. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res 2014; 3(4): 242–9.

Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: Patient selection criteria for adjuvant chemotherapy according to the seventh edition TNM classification. Chest 2011; 140(6): 1494–502.

Shoji F, Haro A, Yoshida T, Ito K, Morodomi Y, Yano T, et al. Prog¬nostic significance of intratumoral blood vessel invasion in pathologic stage IA non-small cell lung cancer. Ann Thorac Surg 2010; 89(3): 864–9.